Adrenomedullin pegol
Bayer discontinues the respiratory medication PEG-ADM
SG Tylor
Bayer’s second-quarter results update revealed a significant decision: the discontinuation of adrenomedullin pegol (PEG-ADM) development, which had progressed to Phase ...
